Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents

Jay Chhablani, Igor Kozak, Francesco Pichi, Megan Chenworth, Maria H. Berrocal, Rumneek Bedi, Rishi P. Singh, Lihteh Wu, Catherine Meyerle, Antonio Marcelo Casella, Ahmad Mansour, Ziad Bashshur, Antonella Scorza, Paola Carrai, Paolo Nucci, J. Fernando Arevalo

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: To report clinical characteristics and treatment outcomes from the largest case series of choroidal neovascularization secondary to central serous chorioretinopathy. Methods: Retrospective analysis of 46 eyes of 43 consecutive subjects. Collected data included demographic details, history of presenting illness, clinical examination details including visual acuity at presentation and follow-up with imaging and treatment details. Main outcome measures were the proportion of eyes that had improved (3 or more lines), stable (within ±1 line), or decreased (3 or more lines) vision at the final visit as compared with baseline examination. Secondary efficacy outcomes included change in visual acuity at final follow-up, number of injections, treatment-free interval, and adverse events. Results: Mean age was 57.56 years (range 29-79 years). Mean follow-up duration was 38.3 months ± 58.9 months. More than 3 lines of improvement in 12 eyes (26%), vision was stable (within ±1 line) in 19 eyes (41.3%), and .3 lines of loss was noted in 6 eyes (13%). Mean change in the number of lines was 1.16 ± 3.74. Mean number of anti-vascular endothelial growth factor injections during the follow-up was 4.45 ± 4.1. The longest treatment-free interval was 8.9 months ± 7.5 months. There were no adverse events noted. Conclusion: Anti-vascular endothelial growth factor therapy as a primary therapy for choroidal neovascularization secondary to central serous chorioretinopathy is safe and efficacious, without any serious adverse events.

Original languageEnglish
Pages (from-to)2489-2497
Number of pages9
JournalRetina
Volume35
Issue number12
DOIs
Publication statusPublished - 2015

Fingerprint

Central Serous Chorioretinopathy
Choroidal Neovascularization
Angiogenesis Inhibitors
Vascular Endothelial Growth Factor A
Visual Acuity
Therapeutics
Injections
Demography
Outcome Assessment (Health Care)

Keywords

  • Anti-vascular endothelial growth factor
  • Central serous chorioretinopathy
  • Choroidal neovascularization
  • CNV
  • CSCR

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Chhablani, J., Kozak, I., Pichi, F., Chenworth, M., Berrocal, M. H., Bedi, R., ... Arevalo, J. F. (2015). Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents. Retina, 35(12), 2489-2497. https://doi.org/10.1097/IAE.0000000000000655

Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents. / Chhablani, Jay; Kozak, Igor; Pichi, Francesco; Chenworth, Megan; Berrocal, Maria H.; Bedi, Rumneek; Singh, Rishi P.; Wu, Lihteh; Meyerle, Catherine; Casella, Antonio Marcelo; Mansour, Ahmad; Bashshur, Ziad; Scorza, Antonella; Carrai, Paola; Nucci, Paolo; Arevalo, J. Fernando.

In: Retina, Vol. 35, No. 12, 2015, p. 2489-2497.

Research output: Contribution to journalArticle

Chhablani, J, Kozak, I, Pichi, F, Chenworth, M, Berrocal, MH, Bedi, R, Singh, RP, Wu, L, Meyerle, C, Casella, AM, Mansour, A, Bashshur, Z, Scorza, A, Carrai, P, Nucci, P & Arevalo, JF 2015, 'Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents', Retina, vol. 35, no. 12, pp. 2489-2497. https://doi.org/10.1097/IAE.0000000000000655
Chhablani, Jay ; Kozak, Igor ; Pichi, Francesco ; Chenworth, Megan ; Berrocal, Maria H. ; Bedi, Rumneek ; Singh, Rishi P. ; Wu, Lihteh ; Meyerle, Catherine ; Casella, Antonio Marcelo ; Mansour, Ahmad ; Bashshur, Ziad ; Scorza, Antonella ; Carrai, Paola ; Nucci, Paolo ; Arevalo, J. Fernando. / Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents. In: Retina. 2015 ; Vol. 35, No. 12. pp. 2489-2497.
@article{3244fb58750e4e7ca5399e18cde6e494,
title = "Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents",
abstract = "Purpose: To report clinical characteristics and treatment outcomes from the largest case series of choroidal neovascularization secondary to central serous chorioretinopathy. Methods: Retrospective analysis of 46 eyes of 43 consecutive subjects. Collected data included demographic details, history of presenting illness, clinical examination details including visual acuity at presentation and follow-up with imaging and treatment details. Main outcome measures were the proportion of eyes that had improved (3 or more lines), stable (within ±1 line), or decreased (3 or more lines) vision at the final visit as compared with baseline examination. Secondary efficacy outcomes included change in visual acuity at final follow-up, number of injections, treatment-free interval, and adverse events. Results: Mean age was 57.56 years (range 29-79 years). Mean follow-up duration was 38.3 months ± 58.9 months. More than 3 lines of improvement in 12 eyes (26{\%}), vision was stable (within ±1 line) in 19 eyes (41.3{\%}), and .3 lines of loss was noted in 6 eyes (13{\%}). Mean change in the number of lines was 1.16 ± 3.74. Mean number of anti-vascular endothelial growth factor injections during the follow-up was 4.45 ± 4.1. The longest treatment-free interval was 8.9 months ± 7.5 months. There were no adverse events noted. Conclusion: Anti-vascular endothelial growth factor therapy as a primary therapy for choroidal neovascularization secondary to central serous chorioretinopathy is safe and efficacious, without any serious adverse events.",
keywords = "Anti-vascular endothelial growth factor, Central serous chorioretinopathy, Choroidal neovascularization, CNV, CSCR",
author = "Jay Chhablani and Igor Kozak and Francesco Pichi and Megan Chenworth and Berrocal, {Maria H.} and Rumneek Bedi and Singh, {Rishi P.} and Lihteh Wu and Catherine Meyerle and Casella, {Antonio Marcelo} and Ahmad Mansour and Ziad Bashshur and Antonella Scorza and Paola Carrai and Paolo Nucci and Arevalo, {J. Fernando}",
year = "2015",
doi = "10.1097/IAE.0000000000000655",
language = "English",
volume = "35",
pages = "2489--2497",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents

AU - Chhablani, Jay

AU - Kozak, Igor

AU - Pichi, Francesco

AU - Chenworth, Megan

AU - Berrocal, Maria H.

AU - Bedi, Rumneek

AU - Singh, Rishi P.

AU - Wu, Lihteh

AU - Meyerle, Catherine

AU - Casella, Antonio Marcelo

AU - Mansour, Ahmad

AU - Bashshur, Ziad

AU - Scorza, Antonella

AU - Carrai, Paola

AU - Nucci, Paolo

AU - Arevalo, J. Fernando

PY - 2015

Y1 - 2015

N2 - Purpose: To report clinical characteristics and treatment outcomes from the largest case series of choroidal neovascularization secondary to central serous chorioretinopathy. Methods: Retrospective analysis of 46 eyes of 43 consecutive subjects. Collected data included demographic details, history of presenting illness, clinical examination details including visual acuity at presentation and follow-up with imaging and treatment details. Main outcome measures were the proportion of eyes that had improved (3 or more lines), stable (within ±1 line), or decreased (3 or more lines) vision at the final visit as compared with baseline examination. Secondary efficacy outcomes included change in visual acuity at final follow-up, number of injections, treatment-free interval, and adverse events. Results: Mean age was 57.56 years (range 29-79 years). Mean follow-up duration was 38.3 months ± 58.9 months. More than 3 lines of improvement in 12 eyes (26%), vision was stable (within ±1 line) in 19 eyes (41.3%), and .3 lines of loss was noted in 6 eyes (13%). Mean change in the number of lines was 1.16 ± 3.74. Mean number of anti-vascular endothelial growth factor injections during the follow-up was 4.45 ± 4.1. The longest treatment-free interval was 8.9 months ± 7.5 months. There were no adverse events noted. Conclusion: Anti-vascular endothelial growth factor therapy as a primary therapy for choroidal neovascularization secondary to central serous chorioretinopathy is safe and efficacious, without any serious adverse events.

AB - Purpose: To report clinical characteristics and treatment outcomes from the largest case series of choroidal neovascularization secondary to central serous chorioretinopathy. Methods: Retrospective analysis of 46 eyes of 43 consecutive subjects. Collected data included demographic details, history of presenting illness, clinical examination details including visual acuity at presentation and follow-up with imaging and treatment details. Main outcome measures were the proportion of eyes that had improved (3 or more lines), stable (within ±1 line), or decreased (3 or more lines) vision at the final visit as compared with baseline examination. Secondary efficacy outcomes included change in visual acuity at final follow-up, number of injections, treatment-free interval, and adverse events. Results: Mean age was 57.56 years (range 29-79 years). Mean follow-up duration was 38.3 months ± 58.9 months. More than 3 lines of improvement in 12 eyes (26%), vision was stable (within ±1 line) in 19 eyes (41.3%), and .3 lines of loss was noted in 6 eyes (13%). Mean change in the number of lines was 1.16 ± 3.74. Mean number of anti-vascular endothelial growth factor injections during the follow-up was 4.45 ± 4.1. The longest treatment-free interval was 8.9 months ± 7.5 months. There were no adverse events noted. Conclusion: Anti-vascular endothelial growth factor therapy as a primary therapy for choroidal neovascularization secondary to central serous chorioretinopathy is safe and efficacious, without any serious adverse events.

KW - Anti-vascular endothelial growth factor

KW - Central serous chorioretinopathy

KW - Choroidal neovascularization

KW - CNV

KW - CSCR

UR - http://www.scopus.com/inward/record.url?scp=84948457680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948457680&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000000655

DO - 10.1097/IAE.0000000000000655

M3 - Article

C2 - 26110597

AN - SCOPUS:84948457680

VL - 35

SP - 2489

EP - 2497

JO - Retina

JF - Retina

SN - 0275-004X

IS - 12

ER -